12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Iclusig ponatinib: Phase III start

Next quarter, Ariad and the U.K. National Cancer Research Institute will begin the U.K. Phase III SPIRIT 3 trial in about 1,000 patients with chronic-phase CML to evaluate switching therapy to 45 mg oral Iclusig once daily following suboptimal response, treatment failure or intolerance to first-line therapy. First-line therapy consists of imatinib or nilotinib.

Last month,...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >